Pacific Biosciences Of California (PACB) EBITDA (2010 - 2026)

Pacific Biosciences Of California's EBITDA history runs 17 years deep, the most recent figure standing at -$8.9 million for Q1 2026.

• In Q1 2026, EBITDA rose 97.92% year-over-year to -$8.9 million; the TTM figure through Mar 2026 stood at -$129.1 million (up 80.35% YoY), while the FY2025 annual figure was -$546.3 million, down 76.44% from the prior year.
• EBITDA was -$8.9 million for Q1 2026 at Pacific Biosciences Of California, up from -$40.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.2 million in Q4 2024 to a low of -$426.1 million in Q1 2025.
• Historically, EBITDA has averaged -$87.3 million across 5 years, with a median of -$72.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA surged 101.55% in 2024, then slumped 3352.34% in 2025.
• A 5-year view of EBITDA shows it stood at -$82.9 million in 2022, then climbed by 3.53% to -$80.0 million in 2023, then soared by 101.55% to $1.2 million in 2024, then plunged by 3352.34% to -$40.3 million in 2025, then jumped by 77.98% to -$8.9 million in 2026.
• The last three EBITDA figures came in at -$8.9 million (Q1 2026), -$40.3 million (Q4 2025), and -$37.9 million (Q3 2025), per Business Quant data.